We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson Hits 52-Week High on Solid Q3, Outlook
Read MoreHide Full Article
Shares of Becton,Dickinson and Company (BDX - Free Report) scaled a new 52-week high of $178.79 on Jul 31, eventually closing nominally lower at $177.21. This translates into an impressive one-year return of roughly 24.1%, significantly higher than the S&P 500’s 9.2%.
The rally was driven by BD’s consistent earnings performance, innovative product pipeline, expanding product portfolio and increasing penetration in the emerging markets. Moreover, the positive full-year 2016 guidance is a key catalyst, in our view.
Notably, BD has beaten the Zacks Consensus Estimate by an average of 5.04% over the last four quarters.
This Zacks Rank #3 (Hold) stock has a market cap of around $37.84 billion while average volume of shares traded over the last three months is roughly 886.6K.
Key Growth Factors
BD reported better-than-expected third-quarter fiscal 2016 earnings of $2.35 per share, which beat the Zacks Consensus Estimate by 16 cents. For fiscal 2016, revenues are anticipated to increase approximately 24.5% to 25%. The company continues to estimate organic revenue growth of approximately 4.5% to 5%.
BD’s innovative product pipeline is a key growth driver. A vast array of regulatory approvals both in the U.S and International markets is helping the company rapidly expand its product portfolio. Moreover, the collaboration with Check-Points will drive demand for BD MAX assays that detect carbapenem-resistant organisms (CRO) in international markets. Both the companies also plan to develop and commercialize a next-generation CRO assay for launch outside the U.S. in 2017 and later in the U.S.
Further, the partnership with Central Admixture Pharmacy Services (CAPS) will allow BD Intelliport Medication Management System customers to buy a portfolio of frequently used CAPS' pre-filled anesthesia syringes.
We believe that these kinds of partnerships and collaborations will lend BD a competitive edge, which will eventually boost its overall results. Although the Zacks Consensus Estimate for full-year 2016 has remained steady at $8.56 over the last 7 days, it reflects year-over-year growth of almost 19.6%.
Key Picks
Better-ranked stocks in the broader medical sector are Natus Medical Inc , Masimo Corporation (MASI - Free Report) and NuVasive Inc . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Becton, Dickinson Hits 52-Week High on Solid Q3, Outlook
Shares of Becton, Dickinson and Company (BDX - Free Report) scaled a new 52-week high of $178.79 on Jul 31, eventually closing nominally lower at $177.21. This translates into an impressive one-year return of roughly 24.1%, significantly higher than the S&P 500’s 9.2%.
The rally was driven by BD’s consistent earnings performance, innovative product pipeline, expanding product portfolio and increasing penetration in the emerging markets. Moreover, the positive full-year 2016 guidance is a key catalyst, in our view.
Notably, BD has beaten the Zacks Consensus Estimate by an average of 5.04% over the last four quarters.
This Zacks Rank #3 (Hold) stock has a market cap of around $37.84 billion while average volume of shares traded over the last three months is roughly 886.6K.
Key Growth Factors
BD reported better-than-expected third-quarter fiscal 2016 earnings of $2.35 per share, which beat the Zacks Consensus Estimate by 16 cents. For fiscal 2016, revenues are anticipated to increase approximately 24.5% to 25%. The company continues to estimate organic revenue growth of approximately 4.5% to 5%.
BECTON DICKINSO Price and Consensus
BECTON DICKINSO Price and Consensus | BECTON DICKINSO Quote
BD’s innovative product pipeline is a key growth driver. A vast array of regulatory approvals both in the U.S and International markets is helping the company rapidly expand its product portfolio. Moreover, the collaboration with Check-Points will drive demand for BD MAX assays that detect carbapenem-resistant organisms (CRO) in international markets. Both the companies also plan to develop and commercialize a next-generation CRO assay for launch outside the U.S. in 2017 and later in the U.S.
Further, the partnership with Central Admixture Pharmacy Services (CAPS) will allow BD Intelliport Medication Management System customers to buy a portfolio of frequently used CAPS' pre-filled anesthesia syringes.
We believe that these kinds of partnerships and collaborations will lend BD a competitive edge, which will eventually boost its overall results. Although the Zacks Consensus Estimate for full-year 2016 has remained steady at $8.56 over the last 7 days, it reflects year-over-year growth of almost 19.6%.
Key Picks
Better-ranked stocks in the broader medical sector are Natus Medical Inc , Masimo Corporation (MASI - Free Report) and NuVasive Inc . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>